Comparative Pharmacology
Head-to-head clinical analysis: OZOBAX versus ROBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZOBAX versus ROBAXIN.
OZOBAX vs ROBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant